Merck nears $1.3 billion cash deal for eye-drug company EyeBio, WSJ reports
Merck & Co is nearing a $1.3 billion cash deal to buy ophthalmology biotechnology company Eyebiotech in an agreement that could see an additional $1.7 billion in milestone payments, the